This bill aims to broaden the scope of opioid overdose reversal agents recognized within Department of Health and Human Services (HHS) grant programs. It directs the Secretary of HHS to ensure that all future regulations and guidance for grant programs addressing opioid misuse and use disorders refer to any FDA-approved opioid overdose reversal drug , rather than exclusively mentioning naloxone. Furthermore, the legislation mandates that within one year of enactment, HHS must update existing references to opioid overdose reversal drugs in guidance and regulations for specific grant programs. These include the State and Tribal Opioid Response Grants and the grant program for priority substance use disorder prevention needs . This ensures that federal support for combating the opioid crisis encompasses the full range of available and approved reversal medications.